• Explore /
  • Poster
  • / Escalated dosing schedules of CC-486 for patients experiencing first acute myeloid leukemia (AML) relapse: Results from the phase III QUAZAR AML-001 maintenance trial.

Escalated dosing schedules of CC-486 for patients experiencing first acute myeloid leukemia (AML) relapse: Results from the phase III QUAZAR AML-001 maintenance trial.

Abstract Video & Slides Poster

Authors

null

Hartmut Dohner

Universitätsklinikum Ulm, Ulm, Germany

Hartmut Dohner , Andrew Wei , Pau Montesinos , Hervé Dombret , Farhad Ravandi , Hamid Sayar , Kimmo Porkka , Irwindeep Sandhu , Francesco Passamonti , Fabrizio Pane , Tadeusz Robak , Jose F. Falantes , Andre C. Schuh , Gert J. Ossenkoppele , Ignazia La Torre , Barry Skikne , Keshava Kumar , Qian Dong , C. L. Beach , Gail J. Roboz

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2020 ASCO Virtual Scientific Program

Session Type

Poster Discussion Session

Session Title

Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant

Track

Hematologic Malignancies

Sub Track

Acute Leukemia

Clinical Trial Registration Number

NCT01757535

Citation

J Clin Oncol 38: 2020 (suppl; abstr 7513)

DOI

10.1200/JCO.2020.38.15_suppl.7513

Abstract #

7513

Poster Bd #

286

Abstract Disclosures

Similar Posters

First Author: Farhad Ravandi

First Author: B. Pro

Poster

2011 ASCO Annual Meeting

A randomized, phase III trial comparing BuCy and BuFlu as a myeloablative conditioning regimen.

A randomized, phase III trial comparing BuCy and BuFlu as a myeloablative conditioning regimen.

First Author: S. Kim

First Author: Stéphane De Botton